The number of apheresis procedures to treat immune-mediated neurological diseases is on the rise
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F25%3A10501599" target="_blank" >RIV/00179906:_____/25:10501599 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/25:E0111868 RIV/00023736:_____/25:00013810
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ZIXFxveT6r" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=ZIXFxveT6r</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.transci.2025.104208" target="_blank" >10.1016/j.transci.2025.104208</a>
Alternative languages
Result language
angličtina
Original language name
The number of apheresis procedures to treat immune-mediated neurological diseases is on the rise
Original language description
Apheresis is used for the treatment of many different diseases, especially when conventional therapy lacks efficacy. There are however some diseases in which apheresis is accepted as first line therapy. The aim of this analysis was to investigate the use of apheresis for the treatment of neurological diseases and the changes over two decades in the World Apheresis Association registry. During the period 2003-2023, a total of 23,699 apheresis procedures in 2963 patients with a neurological disease were performed. Data were collected during different periods by 44 centers, out of which 22 centers had been registering continuously over the latest 10 years. An increase in the proportion of neurological diseases developed over the period (p < 0.001) while the overall apheresis procedures remained stable (p = 0.46). Most procedures were due to myasthenia gravis (MG; n = 11,049 (31 % of patients), Guillain-Barre<acute accent> Syndrome (GBS; n = 3247 (30 %), multiple sclerosis (MS; n = 2665 (18 %)), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP; n = 2367 (3 %)), and neuromyelitis optica (NMO; n = 650 (2 %)). A change in the proportion of these diseases was noted over time. Adverse events (AEs) differed significantly between the diseases. Patients with GBS had most moderate and severe AEs. Hypotension was the most common severe AE. The panorama of different neurological diseases may cause different AEs based on the variation in neurological response to the apheresis procedure and replacement fluid. It is important to expand this knowledge among those who are prescribing and those performing the apheresis procedures.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Transfusion and Apheresis Science
ISSN
1473-0502
e-ISSN
1878-1683
Volume of the periodical
64
Issue of the periodical within the volume
5
Country of publishing house
GB - UNITED KINGDOM
Number of pages
6
Pages from-to
104208
UT code for WoS article
001549753400002
EID of the result in the Scopus database
2-s2.0-105010577731